According to Bloomberg via PharmaGossip, Bayer may be in discussions with Biocompatibles to acquire the specialty drug delivery firm. Bayer is already collaborating with Biocompatibles and its controlled-release, gel-based drug delivery system with Bayer's Nexavar.
Biocompatibles has acknowledged it is in advanced talks with an unidentified potential bidder. Bayer is looked at by analysts as a logical candidate for the bidder role given its Nexavar project, its heavy cash position, and its stated desire to acquire assets in cardiologym, oncology or women's health.
However, rumors are not restricted to Bayer as the potential acquirer. Analysts have also floated companies like Terumo Corp, AngioDynamics, Inc, SciClone Pharmaceuticals, BTG Plc, and AstraZeneca as well. All of these companies have partner projects ongoing with Biocompatibles.
Biocompatibles is trading at 335 pence per share and analysts have pegged its potential value as an acquistion candidate anywhere from 400 to 520 pence per share. Rumored suitor companies all had no comment - DUH!
Posted by Bruce Lehr November 3rd 2010.